Get the Stockscreener App
0.4942
1.40%
-0.007
Pre-market:
.49
-0.0042
-0.85%
Curis Inc stock is traded at $0.4942, with a volume of 134.71K.
It is down -1.40% in the last 24 hours and down -16.96% over the past month.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
See More
Previous Close:
$0.5012
Open:
$0.518
24h Volume:
134.71K
Relative Volume:
0.34
Market Cap:
$19.26M
Revenue:
$9.44M
Net Income/Loss:
$-7.58M
P/E Ratio:
-0.4139
EPS:
-1.194
Net Cash Flow:
$-27.20M
1W Performance:
+3.87%
1M Performance:
-16.96%
6M Performance:
-60.46%
1Y Performance:
-75.29%
1-Day Range:
$0.4941
$0.522
1-Week Range:
$0.4709
$0.522
52-Week Range:
$0.4637
$3.13
Curis Inc Stock (CRIS) Company Profile
Name
Curis Inc
Sector
Industry
Phone
617-503-6500
Address
128 SPRING STREET, LEXINGTON, MA
Compare CRIS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
0.4942 | 19.54M | 9.44M | -7.58M | -27.20M | -1.194 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Apr-04-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-13-21 | Initiated | Raymond James | Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Jul-29-20 | Initiated | Laidlaw | Buy |
| Jul-17-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Mar-02-16 | Initiated | Sun Trust Rbsn Humphrey | Buy |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Aug-11-15 | Initiated | FBR Capital | Outperform |
| Jan-22-15 | Reiterated | Oppenheimer | Outperform |
| Jan-21-15 | Reiterated | ROTH Capital | Buy |
| May-09-14 | Reiterated | Oppenheimer | Outperform |
| Oct-02-13 | Initiated | Robert W. Baird | Outperform |
| Sep-30-13 | Initiated | Chardan Capital Markets | Buy |
| Nov-14-12 | Initiated | Stifel Nicolaus | Hold |
| Jan-31-12 | Reiterated | Brean Murray | Buy |
| Jan-31-12 | Reiterated | Summer Street Research | Buy |
| Dec-09-11 | Initiated | Oppenheimer | Outperform |
| Oct-06-11 | Initiated | Summer Street Research | Buy |
| Sep-22-11 | Initiated | MLV Capital | Buy |
| Mar-21-11 | Reiterated | Brean Murray | Buy |
| Feb-26-10 | Reiterated | Roth Capital | Buy |
| Jan-07-10 | Initiated | Roth Capital | Buy |
View All
Curis Inc Stock (CRIS) Latest News
Curis (NASDAQ: CRIS) wins shareholder approval to double authorized common stock - Stock Titan
CRIS News | CURIS INC (NASDAQ:CRIS) - ChartMill
Curis stock (US2312691006): Phase 1 data update lifts attention - AD HOC NEWS
Curis Inc Annual Shareholders Meeting Transcript - GuruFocus
CRIS: All five shareholder proposals, including director elections and share increase, were approved - TradingView
Curis to Host Webcast to Discuss Updated Emavusertib Clinical Da - GuruFocus
Curis Faces Nasdaq Delisting Determination, Plans Appeal Hearing - TipRanks
Curis stock (US2312691006): cancer pipeline update keeps investors cautious - AD HOC NEWS
Armistice Capital (NASDAQ: CRIS) reports 4.99% ownership of Curis - Stock Titan
JonesTrading Maintains Curis(CRIS.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Thomas Satterfield holds 3.96M shares as Curis (CRIS) ownership amended - Stock Titan
Curis, Inc. (NASDAQ:CRIS) Q1 2026 Earnings Call Transcript - Insider Monkey
Curis Q1 2026 earnings preview - MSN
Curis Inc. Earnings Call Highlights Clinical Momentum - TipRanks
Curis Q1 2026 Deep Dive: EPS Misses by 331.0%, Revenue Down 100% - AlphaStreet
Curis, Inc. (CRIS) Reports Q1 2026 Loss and Updates on Clinical Trials - GuruFocus
CURIS INC 1Q 2026: Revenue $0 Net income ($24.2M), EPS ($1.25) — 10-Q Summary - TradingView
Curis (NASDAQ: CRIS) posts larger Q1 2026 loss and warns on going concern - Stock Titan
Q1 2026 Curis Inc Earnings Call Transcript - GuruFocus
Curis, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Curis anticipates TakeAim CLL initial 5-patient dosing by mid-2026 while projecting cash runway into second half of '27 - MSN
Curis Inc (CRIS) Q1 2026 Earnings Call Highlights: Progress in L - GuruFocus
Curis (CRIS) Expects Sufficient Funding to Support Operations Un - GuruFocus
Earnings call transcript: Curis Q1 2026 reveals widened net loss - Investing.com UK
Curis (CRIS) Reports Q1 Revenue Below Expectations - GuruFocus
Curis Q1 2026 Earnings Call Transcript - MarketBeat
Curis (CRIS) Q1 Miss: EPS -$1.25 vs -$0.40 est, Revenue $0 vs $1 - GuruFocus
Curis Provides First Quarter 2026 Business Update - GuruFocus
Curis Sees Cash Runway Into the 2H of 2027 >CRIS - Moomoo
Earnings call transcript: Curis Q1 2026 reveals widened net loss By Investing.com - Investing.com Nigeria
Curis Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Curis Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Curis reports Q1 loss, expects CLL trial milestone by mid-2026 - Investing.com South Africa
Curis: Q1 Earnings Snapshot - kens5.com
Curis (NASDAQ: CRIS) posts larger Q1 2026 loss and flags funding needs - Stock Titan
Curis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026 - Barchart
CRIS Q1'26 Earnings: EPS estimate is (0.33) USD - TradingView
Number of shareholders of Curis, Inc. – LSX:A3ETJD - TradingView
Curis Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds - Quantisnow
Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024 - Quantisnow
Curis Inc Stock (CRIS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):